GlaxoSmithKine is alerting healthcare professionals that the Company has made the decision to discontinue the commercial availability of Tanzeum (albiglutide for injection; 30mg and 50mg). The Company states that this was not related to any safety concerns regarding the product, but rather due to limited prescribing of the drug.

Tanzeum, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes. It was approved by the Food and Drug Administration (FDA) in 2014. 

Related Articles

As availability of the drug is likely to be depleted by July 2018, the Company is suggesting that clinicians put a plan in place to transition patients currently on Tanzeum to an alternative therapy before this time. In addition, Tanzeum therapy should not be started in any new patients.

A list of alternative GLP-1 receptor agonist therapies can be found here.

For more information call (888) 825-5249 or visit